• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新冠病毒感染康复期的自然杀伤细胞亚群及受体表达

NK Cell Subpopulations and Receptor Expression in Recovering SARS-CoV-2 Infection.

作者信息

Saresella Marina, Trabattoni Daria, Marventano Ivana, Piancone Federica, La Rosa Francesca, Caronni Antonio, Lax Agata, Bianchi Luca, Banfi Paolo, Navarro Jorge, Bolognesi Elisabetta, Zanzottera Milena, Guerini Franca Rosa, Clerici Mario

机构信息

IRCCS Fondazione Don Carlo Gnocchi ONLUS, Via Capecelatro, 66, 20148, Milan, Italy.

Department of Biomedical and Clinical Sciences "L. Sacco,", University of Milan, Milan, Italy.

出版信息

Mol Neurobiol. 2021 Dec;58(12):6111-6120. doi: 10.1007/s12035-021-02517-4. Epub 2021 Aug 28.

DOI:10.1007/s12035-021-02517-4
PMID:34453271
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8397607/
Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the pandemic of coronavirus disease (COVID-19). Whereas in most cases COVID-19 is asymptomatic or pauci-symptomatic, extremely severe clinical forms are observed. In this case, complex immune dysregulations and an excessive inflammatory response are reported and are the main cause of morbidity and mortality. Natural killer cells are key players in the control of viral infection, and their activity is regulated by a tight balance between activating and inhibitory receptors; an alteration of NK activity was suggested to be associated with the development of severe forms of COVID-19. In this study, we analyzed peripheral NK cell subpopulations and the expression of activating and inhibitory receptors in 30 patients suffering from neurological conditions who recovered from mild, moderate, or severe SARS-CoV-2 infection, comparing the results to those of 10 SARS-CoV-2-uninfected patients. Results showed that an expansion of NK subset with lower cytolytic activity and an augmented expression of the 2DL1 inhibitory receptor, particularly when in association with the C2 ligand (KIR2DL1-C2), characterized the immunological scenario of severe COVID-19 infection. An increase of NK expressing the ILT2 inhibitory receptor was instead seen in patients recovering from mild or moderate infection compared to controls. Results herein suggest that the KIR2DL1-C2 NK inhibitory complex is a risk factor toward the development of severe form of COVID-19. Our results confirm that a complex alteration of NK activity is present in COVID-19 infection and offer a molecular explanation for this observation.

摘要

严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引发了冠状病毒病(COVID-19)大流行。虽然在大多数情况下,COVID-19无症状或症状轻微,但也观察到了极其严重的临床形式。在这种情况下,会出现复杂的免疫失调和过度的炎症反应,这是发病和死亡的主要原因。自然杀伤细胞是控制病毒感染的关键因素,其活性由激活受体和抑制受体之间的紧密平衡调节;NK活性的改变被认为与严重形式的COVID-19的发展有关。在本研究中,我们分析了30例从轻度、中度或重度SARS-CoV-2感染中康复的神经系统疾病患者的外周血NK细胞亚群以及激活受体和抑制受体的表达,并将结果与10例未感染SARS-CoV-2的患者进行比较。结果显示,具有较低细胞溶解活性的NK亚群扩增以及2DL1抑制受体表达增加,特别是当与C2配体(KIR2DL1-C2)结合时,是严重COVID-19感染免疫情况的特征。与对照组相比,从轻度或中度感染中康复的患者中表达ILT2抑制受体的NK细胞增加。本文结果表明,KIR2DL1-C2 NK抑制复合物是导致严重形式COVID-19发展的危险因素。我们的结果证实,COVID-19感染中存在NK活性的复杂改变,并为这一观察结果提供了分子解释。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b599/8397607/8abac620b0ed/12035_2021_2517_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b599/8397607/ebd45d392a4a/12035_2021_2517_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b599/8397607/51ae957a977d/12035_2021_2517_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b599/8397607/af62176ccabc/12035_2021_2517_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b599/8397607/08039f87d5eb/12035_2021_2517_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b599/8397607/8abac620b0ed/12035_2021_2517_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b599/8397607/ebd45d392a4a/12035_2021_2517_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b599/8397607/51ae957a977d/12035_2021_2517_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b599/8397607/af62176ccabc/12035_2021_2517_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b599/8397607/08039f87d5eb/12035_2021_2517_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b599/8397607/8abac620b0ed/12035_2021_2517_Fig5_HTML.jpg

相似文献

1
NK Cell Subpopulations and Receptor Expression in Recovering SARS-CoV-2 Infection.新冠病毒感染康复期的自然杀伤细胞亚群及受体表达
Mol Neurobiol. 2021 Dec;58(12):6111-6120. doi: 10.1007/s12035-021-02517-4. Epub 2021 Aug 28.
2
Expansion of CD56CD16 NK Cell Subset and Increased Inhibitory KIRs in Hospitalized COVID-19 Patients.住院 COVID-19 患者中 CD56CD16 NK 细胞亚群扩增和抑制性 KIR 增加。
Viruses. 2021 Dec 28;14(1):46. doi: 10.3390/v14010046.
3
Natural killer-cell immunoglobulin-like receptors trigger differences in immune response to SARS-CoV-2 infection.自然杀伤细胞免疫球蛋白样受体引发对 SARS-CoV-2 感染免疫反应的差异。
PLoS One. 2021 Aug 5;16(8):e0255608. doi: 10.1371/journal.pone.0255608. eCollection 2021.
4
SARS-CoV-2 Immunization Orchestrates the Amplification of IFNγ-Producing T Cell and NK Cell Persistence.SARS-CoV-2 免疫调控 IFNγ 产生的 T 细胞和 NK 细胞持久性扩增。
Front Immunol. 2022 Feb 14;13:798813. doi: 10.3389/fimmu.2022.798813. eCollection 2022.
5
Modulation of the natural killer cell KIR repertoire by cytomegalovirus infection.巨细胞病毒感染对自然杀伤细胞 KIR repertoire 的调节。
Eur J Immunol. 2013 Feb;43(2):480-7. doi: 10.1002/eji.201242389. Epub 2012 Dec 12.
6
NK cell receptor and ligand composition influences the clearance of SARS-CoV-2.自然杀伤细胞受体和配体组成影响 SARS-CoV-2 的清除。
J Clin Invest. 2021 Nov 1;131(21). doi: 10.1172/JCI146408.
7
Discrimination between the main activating and inhibitory killer cell immunoglobulin-like receptor positive natural killer cell subsets using newly characterized monoclonal antibodies.使用新鉴定的单克隆抗体区分主要的活化性和抑制性杀伤细胞免疫球蛋白样受体阳性自然杀伤细胞亚群。
Immunology. 2009 Oct;128(2):172-84. doi: 10.1111/j.1365-2567.2009.03085.x.
8
Siglec-9 Restrains Antibody-Dependent Natural Killer Cell Cytotoxicity against SARS-CoV-2.Siglec-9 抑制针对 SARS-CoV-2 的抗体依赖的自然杀伤细胞细胞毒性。
mBio. 2023 Feb 28;14(1):e0339322. doi: 10.1128/mbio.03393-22. Epub 2023 Feb 2.
9
Individualized Constellation of Killer Cell Immunoglobulin-Like Receptors and Cognate HLA Class I Ligands that Controls Natural Killer Cell Antiviral Immunity Predisposes COVID-19.控制自然杀伤细胞抗病毒免疫的杀伤细胞免疫球蛋白样受体和同源HLA I类配体的个体化组合易患COVID-19。
Front Genet. 2022 Feb 22;13:845474. doi: 10.3389/fgene.2022.845474. eCollection 2022.
10
Activating Killer-Cell Immunoglobulin-Like Receptors Are Associated With the Severity of Coronavirus Disease 2019.激活杀伤细胞免疫球蛋白样受体与 2019 年冠状病毒病的严重程度有关。
J Infect Dis. 2021 Jul 15;224(2):229-240. doi: 10.1093/infdis/jiab228.

引用本文的文献

1
Expression of metabolic genes in NK cells is associated with clinical outcomes in patients with severe COVID-19: a brief report.自然杀伤细胞中代谢基因的表达与重症 COVID-19 患者的临床结局相关:简要报告
Front Cell Infect Microbiol. 2025 Aug 25;15:1636463. doi: 10.3389/fcimb.2025.1636463. eCollection 2025.
2
Identification of severity related mutation hotspots in SARS-CoV-2 using a density-based clustering approach.使用基于密度的聚类方法识别新冠病毒中与严重程度相关的突变热点。
BioData Min. 2025 Sep 1;18(1):61. doi: 10.1186/s13040-025-00476-3.
3
The Role of Killer Ig-like Receptors in Diseases from A to Z.

本文引用的文献

1
Time-resolved systems immunology reveals a late juncture linked to fatal COVID-19.时间分辨系统免疫学揭示了与致命 COVID-19 相关的晚期节点。
Cell. 2021 Apr 1;184(7):1836-1857.e22. doi: 10.1016/j.cell.2021.02.018. Epub 2021 Feb 10.
2
Clinical course of SARS-CoV-2 infection in patients with severe acquired brain injury and a disorder of consciousness: an observational study.严重获得性脑损伤和意识障碍患者感染新型冠状病毒2的临床病程:一项观察性研究
Brain Inj. 2021 Apr 16;35(5):520-529. doi: 10.1080/02699052.2021.1887937. Epub 2021 Feb 15.
3
The role of KIR positive NK cells in diseases and its importance in clinical intervention.
杀伤细胞免疫球蛋白样受体在各种疾病中的作用
Int J Mol Sci. 2025 Mar 31;26(7):3242. doi: 10.3390/ijms26073242.
4
Organ-Dysfunction Markers in Mild-to-Moderate COVID-19 Convalescents.轻至中度新冠康复者的器官功能障碍标志物
J Clin Med. 2024 Apr 12;13(8):2241. doi: 10.3390/jcm13082241.
5
Association of KIR Genes with Middle East Respiratory Syndrome Coronavirus Infection in South Koreans.韩国人群中杀伤细胞免疫球蛋白样受体(KIR)基因与中东呼吸综合征冠状病毒感染的关联
J Clin Med. 2024 Jan 2;13(1):258. doi: 10.3390/jcm13010258.
6
Immune inhibitory receptor-mediated immune response, metabolic adaptation, and clinical characterization in patients with COVID-19.新型冠状病毒肺炎患者免疫抑制受体介导的免疫应答、代谢适应及临床特征
Sci Rep. 2023 Nov 6;13(1):19221. doi: 10.1038/s41598-023-45883-w.
7
Defining the role of natural killer cells in COVID-19.定义自然杀伤细胞在 COVID-19 中的作用。
Nat Immunol. 2023 Oct;24(10):1628-1638. doi: 10.1038/s41590-023-01560-8. Epub 2023 Jul 17.
8
Distribution of KIR Genes and Their HLA Ligands in Different Viral Infectious Diseases: Frequency Study in Sicilian Population.不同病毒感染性疾病中 KIR 基因及其 HLA 配体的分布:西西里人群的频率研究。
Int J Mol Sci. 2022 Dec 7;23(24):15466. doi: 10.3390/ijms232415466.
9
Innate immune responses to three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine.三种剂量 BNT162b2 mRNA SARS-CoV-2 疫苗的先天免疫应答。
Front Immunol. 2022 Aug 22;13:947320. doi: 10.3389/fimmu.2022.947320. eCollection 2022.
10
Exploring the Utility of NK Cells in COVID-19.探索自然杀伤细胞在新型冠状病毒肺炎中的作用
Biomedicines. 2022 Apr 26;10(5):1002. doi: 10.3390/biomedicines10051002.
KIR 阳性 NK 细胞在疾病中的作用及其在临床干预中的重要性。
Int Immunopharmacol. 2021 Mar;92:107361. doi: 10.1016/j.intimp.2020.107361. Epub 2021 Jan 8.
4
Human Diversity of Killer Cell Immunoglobulin-Like Receptors and Human Leukocyte Antigen Class I Alleles and Ebola Virus Disease Outcomes.杀伤细胞免疫球蛋白样受体和人类白细胞抗原 I 类等位基因的人类多样性与埃博拉病毒病结局。
Emerg Infect Dis. 2021 Jan;27(1):76-84. doi: 10.3201/eid2701.202177.
5
Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19.重症 COVID-19 患者自然杀伤细胞计数和细胞溶解活性受损。
Blood Adv. 2020 Oct 27;4(20):5035-5039. doi: 10.1182/bloodadvances.2020002650.
6
Programmed cell death 1-expressing CD56-negative natural killer (NK) cell expansion is a hallmark of chronic NK cell activation during dasatinib treatment.达沙替尼治疗期间,程序性细胞死亡受体 1 表达的 CD56 阴性自然杀伤(NK)细胞扩增是慢性 NK 细胞激活的标志。
Cancer Sci. 2021 Feb;112(2):523-536. doi: 10.1111/cas.14692. Epub 2020 Dec 16.
7
Unique immunological profile in patients with COVID-19.COVID-19 患者的独特免疫特征。
Cell Mol Immunol. 2021 Mar;18(3):604-612. doi: 10.1038/s41423-020-00557-9. Epub 2020 Oct 15.
8
Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19.新型冠状病毒肺炎中自然杀伤细胞上可成药的抑制性免疫检查点的鉴定
Cell Mol Immunol. 2020 Sep;17(9):995-997. doi: 10.1038/s41423-020-0493-9. Epub 2020 Jul 1.
9
A single-cell atlas of the peripheral immune response in patients with severe COVID-19.严重 COVID-19 患者外周免疫反应的单细胞图谱。
Nat Med. 2020 Jul;26(7):1070-1076. doi: 10.1038/s41591-020-0944-y. Epub 2020 Jun 8.
10
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.人类单克隆 SARS-CoV 抗体对 SARS-CoV-2 的交叉中和作用。
Nature. 2020 Jul;583(7815):290-295. doi: 10.1038/s41586-020-2349-y. Epub 2020 May 18.